CGONNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31

CG Oncology, Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026

$59.96+0.11 (+0.18%)

Close on Oct 19, 2026

Market cap: $5.29B
P/E (TTM): –
Dividend yield: –

CG Oncology, Inc. balance sheet

Annual Quarterly

Millions of USD, except per-share data. Shares in millions.

Line item	Q2 2026 2026-06-30	Q1 2026 2026-03-31	Q4 2025 2025-12-31	Q3 2025 2025-09-30	Q2 2025 2025-06-30	Q1 2025 2025-03-31	Q4 2024 2024-12-31	Q3 2024 2024-09-30	Q2 2024 2024-06-30	Q1 2024 2024-03-31	Q4 2023 2023-12-31	Q3 2023 2023-09-30	Q2 2023 2023-06-30	Q1 2023 2023-03-31	Q4 2022 2022-12-31
Cash & Equivalents	20	34	32	45	15	41	257	43	25	77	8.27	10	78	0.69	88
Short-Term Investments	1,009	1,043	710	635	646	647	485	497	528	489	179	–	–	–	–
Cash & Short-Term Investments	1,028	1,076	742	680	661	688	742	541	553	567	188	10	78	0.69	88
Receivables	0.42	1.28	0.69	0.52	–	–	0	–	–	–	–	–	–	–	–
Inventory	1.00	1.49	1.57	1.50	–	–	0	–	–	–	–	–	–	–	–
Prepaid Expenses & Other	20	23	15	14	11	12	12	11	11	12	6.36	–	–	–	–
Total Current Assets	1,050	1,102	759	696	673	701	754	552	564	579	194	–	–	–	–
Property, Plant & Equipment	15	15	16	15	0.25	0.26	0.27	0.06	0.08	0.08	0.07	–	–	–	–
Gross Property, Plant & Equipment	18	17	17	16	–	–	0.36	–	–	–	–	–	–	–	–
Accumulated Depreciation	-3.13	-2.29	-1.47	-0.62	–	–	-0.09	–	–	–	–	–	–	–	–
Operating Lease Right-of-Use Assets	5.73	4.51	3.97	4.20	0.97	1.03	0.22	0.28	0.33	0.37	0.42	–	–	–	–
Goodwill	10	10	10	13	–	–	0	–	–	–	–	–	–	–	–
Intangible Assets	0.55	0.56	0.58	1.67	–	–	0	–	–	–	–	–	–	–	–
Other Long-Term Assets	4.73	2.68	1.68	0.11	0.52	0.52	0.09	0.05	0.05	0.05	0.02	–	–	–	–
Total Assets	1,086	1,135	792	730	701	728	755	552	564	579	199	–	–	–	–
Accounts Payable	13	8.24	5.71	9.19	7.13	6.73	6.52	4.08	4.49	4.66	3.24	–	–	–	–
Current Portion of Leases	0.99	1.07	0.92	0.91	0.29	0.26	0.19	0.23	0.24	0.22	0.22	–	–	–	–
Total Current Liabilities	47	35	31	31	30	23	21	16	12	9.98	14	–	–	–	–
Long-Term Debt	3.00	3.00	3.00	3.00	–	–	0	–	–	–	–	–	–	–	–
Long-Term Leases	4.83	3.51	3.11	3.33	0.71	0.78	0.05	0.07	0.12	0.18	0.24	–	–	–	–
Operating Lease Liabilities	5.82	4.58	4.02	4.24	0.99	1.04	0.24	0.30	0.36	0.40	0.46	–	–	–	–
Other Long-Term Liabilities	1.16	1.45	1.74	3.80	–	–	0	–	–	–	–	–	–	–	–
Total Liabilities	57	43	39	42	31	23	21	16	12	10	15	–	–	–	–
Total Debt	3.00	3.00	3.00	3.00	–	–	0	–	–	–	–	–	–	–	–
Common Stock	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01	–	–	–	–	–
Additional Paid-In Capital	1,547	1,531	1,132	1,025	964	957	951	723	718	716	6.84	–	–	–	–
Retained Earnings	-518	-439	-379	-338	-294	-252	-218	-186	-166	-147	-130	–	–	–	–
Shareholders' Equity	1,029	1,092	753	688	670	705	733	537	552	569	-123	-108	-97	-86	-78
Total Equity	1,029	1,092	753	688	670	705	733	537	552	569	-123	-108	-97	-86	-78
Total Liabilities & Equity	1,086	1,135	792	730	701	728	755	552	564	579	199	–	–	–	–
Shares Outstanding(shares)	88	88	81	78	76	76	76	68	67	67	5.22	–	–	–	–

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin: –
Operating margin: -4056.2%
Net margin: -3602.7%
Return on equity, FY2025: -21.7%

Financial strength

Current ratio: 22.22
Debt to equity: 0.00
Debt to assets: 0.3%
Cash to current liabilities: 41.6%

Valuation

P/E ratio: –
Price to sales: 849.14
Price to book: 5.14
Dividend yield: –